<DOC>
	<DOCNO>NCT01950871</DOCNO>
	<brief_summary>The primary objective PHSTT-01 trial determine prostate HistoScanning ( HS ) analysis use improve detection clinically significant prostate cancer ( PCa ) , potentially reduce burden number biopsy routine clinical practice . Prostate HS ultrasound-based tissue characterization technology specifically develop detect , visualize , locate tissue suspect harbor PCa . These suspicious tissue display red area image monitor . Recently new biopsy guidance tool develop us result prostate HS analysis . The subject participate study schedule first biopsy prostate . They initially image use transrectal ultrasound ( TRUS ) obtain data prostate HS analysis . The result HS analysis use later procedure . Subjects undergo routine systematic 10- 12-core biopsy procedure use TRUS . This follow TRUS-guided biopsy use result prostate HS analysis new biopsy guidance tool .</brief_summary>
	<brief_title>Prostate Guided Biopsy Study Evaluating Diagnostic Performance Prostate HistoScanning</brief_title>
	<detailed_description>PHSTT-01 multi-center , prospective clinical trial evaluate diagnostic performance prostate HistoScanning ( HS ) analysis men risk PCa schedule first prostate biopsy . The purpose study determine prostate HS analysis improve detection clinically significant PCa , potentially reduce burden number biopsy routine clinical practice . Subjects men serum total prostate-specific antigen ( PCA ) &lt; = 20ng/mL ( &lt; = 10ng/mL take 5-alpha reductase inhibitor ) . In single visit , subject first image TRUS purpose generate data prostate HS analysis . The result HS analysis use later procedure . Subjects undergo two consecutive biopsy procedure . First , use TRUS , systematic 10- 12-core biopsy procedure perform . In turn , prostate HS data take beginning procedure use determine suspicious area ( display red imaging monitor ) use guide biopsy procedure . Areas identify suspicious ( zero maximum 3 area ) sample two biopsy core . Depending number suspicious area identify prostate HS , number core zero maximum 6 core .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Men risk PCa schedule first biopsy serum total PSA ≤ 20 ng/ml ( ≤ 10 ng/mL take 5alpha reductase inhibitor ) maximally 3 month ago Signed inform consent Previous prostate biopsy Confirmed PCa PSA &gt; 20 ng/ml ( &gt; 10 ng/mL take 5alpha reductase inhibitor ) Active urinary tract infection Presence/history confirm cancer Recent prostatic surgery ( past 6 month ) History pelvic radiotherapy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>HistoScanning</keyword>
	<keyword>TRUS</keyword>
	<keyword>Prostate cancer</keyword>
	<keyword>Biopsy guidance</keyword>
</DOC>